MTOR and colorectal carcinoma: We then tested the effect of the PI3K/mTOR dual inhibitors (Apitolisib and Dactolisib) combined with radiotherapy (1Gy daily fractions for 5 days) on survival of CRC cells (HCT116) and how these compared with 5FU treatment.